Acacia’s PONV drug under US review
US regulators have accepted for review Cambridge, UK-based Acacia Pharma’s application for post-operative nausea and vomiting (PONV) drug Baremsis.
Read More
Tag: Baremsis
UK’s Acacia to file rescue PONV drug in the US
UK firm Acacia Pharma says a fourth and pivotal late-stage study assessing Baremsis as a rescue treatment for patients experiencing post-operative nausea & vomiting (PONV) despite prophylactic therapy has hit its targets, pushing the drug closer to US filing.
Read More
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
